Nvidia and Eli Lilly announced a five‑year, up‑to‑$1 billion co‑investment to create an AI drug‑discovery laboratory in San Francisco. Lilly will supply biological data and drug discovery expertise; Nvidia will supply compute, model development and engineering. The partnership aims to generate large‑scale datasets and AI models to accelerate target identification and candidate design. The deal builds on a wave of chipmaker–pharma collaborations and reflects pharma’s push to vertically integrate AI into discovery workflows. Nvidia also disclosed broader partnerships across life sciences infrastructure and commercialization, signalling an industry‑wide bet that compute and large, curated datasets will reshape preclinical timelines.